Immune classifications with cytotoxic CD8(+) and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Archive ouverte

Madkouri, Rachid | Kaderbhai, Coureche Guillaume | Bertaut, Aurélie | Truntzer, Caroline | Vincent, Julie | Aubriot-Lorton, Marie Hélene | Farah, Walid | Limagne, Emeric | Ladoire, Sylvain | Boidot, Romain | Derangère, Valentin | Ghiringhelli, François

Edité par CCSD ; Taylor & Francis -

IF 7.719. International audience. Background: Interest is growing on immune cells involvement in central nervous system tumors such as glioblastoma. Even if a few reports highlighted that immune classifications could have a prognostic value, no paradigm has been clearly yet established on large and homogeneous cohorts. The aim of our study was to analyze the prognostic role of the in situ immune response of cytotoxic T cells (i.e., CD8(+)), Foxp3 cells, Th17 and tumor-associated macrophages in glioblastoma on two independent large and homogeneous cohorts.Methods: We worked on two large homogenous cohorts of patients having glioblastoma who underwent standard radiochemotherapy. The first cohort of 186 patients was analyzed using IHC procedures (CD8(+), IL-17A, FoxP3 and CD163) of surgery pieces. We next worked with transcriptomic data available online and used metagene strategy analysis for the second cohort of 525 patients.Results: Cytotoxic CD8(+) lymphocytes and Foxp3 cells were associated with a good prognosis, while Th17 were associated with a poor clinical outcome. These data were confirmed with transcriptomic analysis. Moreover, we showed for the first time a strong link between angiogenesis and Th17 metagenes expressions in glioblastoma.Conclusions: Our study shows that glioblastoma bearing patients can be classified on the immune infiltrate aspects. Beyond this prognostic role of immune biomarkers, subsequent classifications could definitely help clinicians to handle targeted therapy administration and immunotherapeutic interventions.

Consulter en ligne

Suggestions

Du même auteur

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

Archive ouverte | Bertaut, Aurélie | CCSD

IF 5.008 . International audience. Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the radiochemotherapy then be...

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Archive ouverte | Derangère, Valentin | CCSD

IF 5.008 . International audience. Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whet...

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

Archive ouverte | Ledys, Fanny | CCSD

IF 8.374 (2018). International audience. BACKGROUND: T lymphocytes and HLA expression on tumor cell both influence prognostic of localized colorectal cancer, but their role following chemotherapy in patients with li...

Chargement des enrichissements...